[HTML][HTML] Emerging role of PARP inhibitors in metastatic triple negative breast cancer. Current scenario and future perspectives
G Barchiesi, M Roberto, M Verrico, P Vici… - Frontiers in …, 2021 - frontiersin.org
Triple negative tumors represent 15% of breast cancer and are characterized by the lack of
estrogen receptors, progesterone receptor, and HER2 amplification or overexpression. …
estrogen receptors, progesterone receptor, and HER2 amplification or overexpression. …
Focus on genetic and epigenetic events of colorectal cancer pathogenesis: implications for molecular diagnosis
F Zoratto, L Rossi, M Verrico, A Papa, E Basso, A Zullo… - Tumor Biology, 2014 - Springer
Originally, colorectal cancer (CRC) tumorigenesis was understood as a multistep process that
involved accumulation of tumor suppressor genes and oncogenes mutations, such as APC…
involved accumulation of tumor suppressor genes and oncogenes mutations, such as APC…
[HTML][HTML] Bevacizumab in ovarian cancer: A critical review of phase III studies
L Rossi, M Verrico, E Zaccarelli, A Papa, M Colonna… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Bevacizumab (BV) is a humanized monoclonal antibody targeting vascular endothelial
growth factor and it is the first molecular-targeted agent to be used for the treatment of ovarian …
growth factor and it is the first molecular-targeted agent to be used for the treatment of ovarian …
[PDF][PDF] Capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs): a systematic review and pooled analysis
G Arrivi, M Verrico, M Roberto, G Barchiesi… - Cancer Management …, 2022 - Taylor & Francis
Background Retrospective studies and single center experiences suggest a role of capecitabine
combined with temozolomide (CAPTEM) in neuroendocrine tumors (NENs). Methods …
combined with temozolomide (CAPTEM) in neuroendocrine tumors (NENs). Methods …
NETest: a systematic review focusing on the prognostic and predictive role
…, R Centello, C Pandozzi, MG Tarsitano, M Verrico… - …, 2022 - karger.com
The NETest is a standardized and reproducible liquid biopsy for neuroendocrine tumors (NETs).
It evaluates the expression of 51 NET genes by real-time polymerase chain reaction, …
It evaluates the expression of 51 NET genes by real-time polymerase chain reaction, …
Clinical management and follow-up of squamous intraepithelial cervical lesions during pregnancy and postpartum
A Frega, P Scirpa, R Corosu, M Verrico… - Anticancer …, 2007 - ar.iiarjournals.org
Background: The incidence of cervical cancer in pregnancy is estimated to be 1-10/10000
pregnancies. Approximately 3% of cervical cancers are diagnosed during pregnancy. The …
pregnancies. Approximately 3% of cervical cancers are diagnosed during pregnancy. The …
[HTML][HTML] Surgical and survival outcomes with perioperative or neoadjuvant immune-checkpoint inhibitors combined with platinum-based chemotherapy in resectable …
…, R Giusti, AJ Gelibter, M Roberto, M Verrico… - Critical Reviews in …, 2023 - Elsevier
The use of neoadjuvant or perioperative anti-PD(L)1 was recently tested in multiple clinical
trials. We performed a systematic review and meta-analysis of randomised trials comparing …
trials. We performed a systematic review and meta-analysis of randomised trials comparing …
[HTML][HTML] Neuroendocrine carcinomas with atypical proliferation index and clinical behavior: a systematic review
Simple Summary Neuroendocrine carcinomas (NECs) are generally highly proliferative and
clinically aggressive neuroendocrine neoplasms, but recent literature data suggested that …
clinically aggressive neuroendocrine neoplasms, but recent literature data suggested that …
[HTML][HTML] Prognostic significance of laterality in lung neuroendocrine tumors
A La Salvia, I Persano, A Siciliani, M Verrico, M Bassi… - Endocrine, 2022 - Springer
Purpose: Well-differentiated lung neuroendocrine tumors (Lu-NET) are classified as typical (TC)
and atypical (AC) carcinoids, based on mitotic counts and necrosis. However, …
and atypical (AC) carcinoids, based on mitotic counts and necrosis. However, …
Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with locally advanced breast cancer treated with …
Purpose Many studies have indicated that the response to therapy and the prognostic impact
of a pathologic complete response after neoadjuvant treatment differ among breast cancer …
of a pathologic complete response after neoadjuvant treatment differ among breast cancer …